Liquidia (LQDA) vs Supernus Pharmaceuticals (SUPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Liquidia (LQDA) has outperformed Supernus Pharmaceuticals (SUPN) over the past year, gaining 11.0% versus a loss of 10.4%. Over five years, LQDA leads with a +733.8% price change compared with +36.0% for SUPN. Liquidia is the larger company by market cap ($2.52 billion vs $2.43 billion), about 1.0 times the size.
On valuation, Supernus Pharmaceuticals trades at a lower forward P/E (9.4x vs 11.7x for Liquidia).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LQDA | SUPN |
|---|---|---|
| Share price | $28.11 | $41.71 |
| Market cap | $2.52B | $2.43B |
| 1-day change | +5.34% | -3.11% |
| YTD return | -22.64% | -13.38% |
| 1-year return | +11.03% | -10.44% |
| 5-year return | +733.75% | +35.98% |
| P/E ratio (TTM) | 20.22 | — |
| Forward P/E | 11.69 | 9.35 |
| EPS (TTM) | $1.39 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $718.95M |
| Revenue growth (YoY) | — | +8.63% |
| Net income (latest FY) | — | $-38.55M |
| Gross margin | — | 89.63% |
| Operating margin | — | -8.66% |
| Net margin | — | -5.36% |
| 52-week high | $93.61 | $59.68 |
| 52-week low | $21.94 | $40.51 |
| Distance from 52-week high | -69.98% | -30.11% |
| Analyst consensus | buy | none |
| Avg. price target upside | +76.73% | +48.05% |
| Average volume | 2.40M | 766.52K |
| Shares outstanding | 89.51M | 58.22M |
| Employees | 216 | 778 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LQDA has outperformed SUPN by 21.5 percentage points over the past year.
About Liquidia
LQDA stock →Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
About Supernus Pharmaceuticals
SUPN stock →Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD.
Health Care · Biotechnology: Pharmaceutical Preparations · 778 employees
LQDA vs SUPN FAQ
Which is bigger, Liquidia or Supernus Pharmaceuticals?
Liquidia (LQDA) is larger, with a market capitalization of $2.52B compared with $2.43B for Supernus Pharmaceuticals (SUPN).
Which stock has performed better over the past year, LQDA or SUPN?
LQDA returned +11.03% over the past 12 months, compared with -10.44% for SUPN (price return, excluding dividends). Past performance does not predict future results.
Are Liquidia and Supernus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.